期刊
NATURE REVIEWS DRUG DISCOVERY
卷 14, 期 4, 页码 279-294出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nrd4578
关键词
-
资金
- NIH predoctoral fellowship [F30 DK092026-01]
- Pharmaceutical Research and Manufacturers of America Foundation predoctoral pharmacology/toxicology fellowship
- Mayo Foundation
- intramural programme in the National Center for Advancing Translational Sciences (NCATS), at the NIH
- NIH
- Minnesota Partnership for Biotechnology and Medical Genomics
The number of academic drug discovery centres has grown considerably in recent years, providing new opportunities to couple the curiosity-driven research culture in academia with rigorous preclinical drug discovery practices used in industry. To fully realize the potential of these opportunities, it is important that academic researchers understand the risks inherent in preclinical drug discovery, and that translational research programmes are effectively organized and supported at an institutional level. In this article, we discuss strategies to mitigate risks in several key aspects of preclinical drug discovery at academic drug discovery centres, including organization, target selection, assay design, medicinal chemistry and preclinical pharmacology.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据